Ginkgo Bioworks to Hold Special Meeting of Shareholders
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced a special meeting of shareholders to be held virtually on August 14, 2024, at 4:00 pm ET. The primary purpose of this meeting is to vote on permitting a reverse stock split of the company's Class A and Class B common stock. The proposed split ratio ranges from 1:20 to 1:40, with the final ratio to be determined by the Board of Directors.
Shareholders will also vote on approving Ginkgo's Amended and Restated Certificate of Incorporation, which includes updates to permit officer exculpation and remove outdated provisions. Detailed information about the meeting and voting procedures can be found in the proxy materials filed with the SEC.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ha annunciato un incontro speciale degli azionisti che si terrà virtualmente il 14 agosto 2024, alle 16:00 ET. Lo scopo principale di questo incontro è votare per consentire uno scorporo azionario inverso delle azioni ordinarie di Classe A e Classe B della società. Il rapporto di scorporo proposto varia da 1:20 a 1:40, con il rapporto finale che sarà determinato dal Consiglio di Amministrazione.
Gli azionisti voteranno anche per approvare il Certificato di Incorporazione Modificato e Ripristinato di Ginkgo, che include aggiornamenti per consentire l'esonero degli ufficiali e rimuovere disposizioni obsolete. Informazioni dettagliate sull'incontro e sulle procedure di voto sono disponibili nei materiali di delega depositati presso la SEC.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ha anunciado una asamblea especial de accionistas que se llevará a cabo de manera virtual el 14 de agosto de 2024, a las 4:00 p.m. ET. El propósito principal de esta reunión es votar sobre la autorización de un desdoblamiento de acciones inverso de las acciones ordinarias de Clase A y Clase B de la compañía. La proporción de desdoblamiento propuesta varía de 1:20 a 1:40, con la proporción final que será determinada por la Junta Directiva.
Los accionistas también votarán para aprobar el Certificado de Incorporación Enmendado y Restablecido de Ginkgo, que incluye actualizaciones para permitir la exención de responsables y eliminar disposiciones obsoletas. La información detallada sobre la reunión y los procedimientos de votación se puede encontrar en los materiales de poder presentados a la SEC.
징코 바이오웍스 홀딩스 주식회사 (NYSE: DNA)가 2024년 8월 14일 오후 4시(ET)에 가상으로 주주총회를 개최한다고 발표했습니다. 이번 회의의 주요 목적은 회사의 A 클래스 및 B 클래스 보통주에 대해 주식 분할을 허용하는 것입니다. 제안된 분할 비율은 1:20에서 1:40까지 다양하며, 최종 비율은 이사회에서 결정됩니다.
주주들은 또한 징코의 수정 및 재신고된 정관을 승인하는 투표도 진행할 예정이며, 이는 임원의 면책을 허용하고 구식 조항을 제거하는 내용을 포함합니다. 회의 및 투표 절차에 대한 자세한 정보는 SEC에 제출된 위임장 자료에서 확인할 수 있습니다.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) a annoncé la tenue d'une assemblée générale extraordinaire des actionnaires qui se déroulera virtuellement le 14 août 2024 à 16h00 ET. Le but principal de cette réunion est de voter sur l'autorisation d'une division d'actions inversée des actions ordinaires de Classe A et Classe B de la société. Le ratio de division proposé varie de 1:20 à 1:40, le ratio final devant être déterminé par le Conseil d'Administration.
Les actionnaires voteront également pour approuver le Certificat de Constitution Modifié et Restitué de Ginkgo, qui comprend des mises à jour visant à permettre l'exonération des dirigeants et à supprimer des dispositions obsolètes. Des informations détaillées sur l'assemblée et les procédures de vote peuvent être trouvées dans les documents de procuration déposés auprès de la SEC.
Die Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) hat eine außerordentliche Versammlung der Aktionäre angekündigt, die am 14. August 2024 um 16:00 Uhr ET virtuell stattfinden wird. Der Hauptzweck dieser Versammlung besteht darin, über die Genehmigung einer Umkehraktienaufspaltung der Stammaktien der Klassen A und B des Unternehmens abzustimmen. Das vorgeschlagene Spaltungsverhältnis reicht von 1:20 bis 1:40, wobei das endgültige Verhältnis vom Vorstand festgelegt wird.
Die Aktionäre werden auch über die Genehmigung von Ginkgos Änderung und Neufassung der Satzung abstimmen, die Aktualisierungen zur Erlaubnis der Entlastung von Führungskräften und zur Streichung veralteter Bestimmungen enthalten. Detaillierte Informationen zur Versammlung und zu den Abstimmungsverfahren finden Sie in den bei der SEC eingereichten Proxy-Materialien.
- Potential for improved stock price through reverse stock split
- Updated Certificate of Incorporation to align with current business needs
- Possible indication of struggling stock price
- Potential dilution of shareholder value through reverse split
Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET
Additional information regarding the special meeting, including how to vote, are available via proxy materials filed by Ginkgo with the
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-hold-special-meeting-of-shareholders-302210173.html
SOURCE Ginkgo Bioworks
FAQ
When is Ginkgo Bioworks (DNA) holding its special shareholder meeting?
What is the main purpose of Ginkgo Bioworks' (DNA) special shareholder meeting?
What changes are proposed in Ginkgo Bioworks' (DNA) Amended and Restated Certificate of Incorporation?
What is the proposed reverse stock split ratio for Ginkgo Bioworks (DNA)?
